Melatonin

From Wikipedia, the free encyclopedia
  (Redirected from Dim light melatonin onset)
Jump to: navigation, search
Not to be confused with Melanin or Melanotan.
Question book-new.svg
 This article relies on references to primary sources or sources affiliated with the subject, rather than references from independent authors and third-party publications. Please add citations from reliable sources. (March 2012)
Melatonin
Systematic (IUPAC) name
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]
acetamide
Clinical data
AHFS/Drugs.com Consumer Drug Information
Pregnancy cat.  ?
Legal status Prescription Only (S4) (AU) ? (UK) OTC (US)
Routes In humans: orally, as capsules, tablets or liquid, sublingually, or as transdermal patches. In lab animals: also injection.
Pharmacokinetic data
Bioavailability 30 – 50%
Metabolism Hepatic via CYP1A2 mediated 6-hydroxylation
Half-life 35 to 50 minutes
Excretion Urine
Identifiers
CAS number 73-31-4 YesY
ATC code N05CH01
PubChem CID 896
IUPHAR ligand 224
DrugBank DB01065
ChemSpider 872 YesY
UNII JL5DK93RCL YesY
KEGG D08170 YesY
ChEBI CHEBI:16796 N
ChEMBL CHEMBL45 YesY
Chemical data
Formula C13H16N2O2 
Mol. mass 232.278 g/mol
SMILES eMolecules & PubChem
 N (what is this?)  (verify)

Melatonin Listeni/ˌmɛləˈtoʊnɪn/, also known chemically as N-acetyl-5-methoxytryptamine,[1] is a naturally occurring compound found in animals, plants, and microbes.[2][3] In animals, circulating levels of the hormone melatonin vary in a daily cycle, thereby allowing the entrainment of the circadian rhythms of several biological functions.[4]

Many biological effects of melatonin are produced through activation of melatonin receptors,[5] while others are due to its role as a pervasive and powerful antioxidant,[6] with a particular role in the protection of nuclear and mitochondrial DNA.[7]

In mammals, melatonin is biosynthesized in four enzymatic steps from the essential dietary amino acid tryptophan, with serotonin produced at the second step. Melatonin is secreted into the blood by the pineal gland in the brain. Known as the "hormone of darkness", it is secreted in darkness in both day-active (diurnal) and night-active (nocturnal) animals.[8] It may also be produced by a variety of peripheral cells such as bone marrow cells,[9][10] lymphocytes, and epithelial cells. Usually, the melatonin concentration in these cells is much higher than that found in the blood, but it does not seem to be regulated by the photoperiod.

Research has shown that when bird chicks ingest melatonin-rich plant feed, such as rice, the melatonin binds to melatonin receptors in their brains.[11] No food has been found to elevate plasma melatonin levels in humans.[12] Products containing melatonin have been available over-the-counter in the United States since the mid-1990s.[13] In many other countries, the over-the-counter sale of this neurohormone is not permitted or requires a prescription, and the U.S. Postal Service lists melatonin as prohibited from being shipped to Germany.[14]

Contents

[edit] Medical uses

Melatonin has been studied for the treatment of cancer, immune disorders, cardiovascular diseases, depression, seasonal affective disorder (SAD), circadian rhythm sleep disorders and sexual dysfunction. It may ameliorate circadian misalignment and SAD.[15] Basic research indicates that melatonin may play a significant role in modulating the effects of drugs of abuse such as cocaine.[16] Melatonin is also a geroprotector.

[edit] Circadian rhythm disorders

Exogenous melatonin taken in the evening is, together with light therapy upon awakening, the standard treatment for delayed sleep phase syndrome (DSPS) and non-24-hour sleep-wake syndrome. It appears to have some use against other circadian rhythm sleep disorders as well, such as jet lag and the problems of people who work rotating or night shifts. Melatonin reduces sleep onset latency to a greater extent in people with DSPS than in people with insomnia.[17]

A very small dose taken several hours before bedtime in accordance with the phase response curve for melatonin in humans (PRC) doesn't cause sleepiness but, acting as a chronobiotic (affecting aspects of biological time structure),[18] advances the phase slightly and is additive to the effect of using light therapy upon awakening. Light therapy may advance the phase about one to two-and-a-half hours and a small oral dose of melatonin, timed correctly some hours before bedtime, can add about 30 minutes to the advance achieved with light therapy.[19]

The World Health Organization in 2007 named late night shift work as a probable cancer-causing agent.[20] Melatonin is an anti-oxidant and suppressant of tumor development that is produced at night; when someone works in artificial light, they generally have lower melatonin and may be more likely to develop cancer. Melatonin supplements may simulate the melatonin production at different times that does not occur during regular sleeping hours for people who work night shifts.[20]

[edit] Learning, memory and Alzheimer's

Melatonin receptors appear to be important in mechanisms of learning and memory in mice,[21] and melatonin can alter electrophysiological processes associated with memory, such as long-term potentiation (LTP). The first published evidence that melatonin may be useful in Alzheimer's disease was the demonstration that this neurohormone prevents neuronal death caused by exposure to the amyloid beta protein, a neurotoxic substance that accumulates in the brains of patients with the disorder.[22] Melatonin also inhibits the aggregation of the amyloid beta protein into neurotoxic microaggregates that, it seems, underlie the neurotoxicity of this protein, causing death of neurons and formation of neurofibrillary tangles, the other neuropathological landmark of Alzheimer's disease.[23]

Melatonin has been shown to prevent the hyperphosphorylation of the tau protein in rats. Hyperphosphorylation of tau protein can also result in the formation of neurofibrillary tangles. Studies in rats suggest that melatonin may be effective for treating Alzheimer's disease.[24] These same neurofibrillary tangles can be found in the hypothalamus in patients with Alzheimer's, adversely affecting their bodies' production of melatonin. Those Alzheimer's patients with this specific affliction often show heightened afternoon agitation, called sundowning, which has been shown in many studies to be effectively treated with melatonin supplements in the evening.[25]

[edit] Delirium

A randomized placebo-controlled trial showed that low-dose melatonin supplementation to 72 elderly patients admitted to acute medicine services significantly reduced delirium. [26]

[edit] Stimulants

Research shows that after melatonin is administered to ADHD patients on methylphenidate, the time needed to fall asleep is significantly reduced. Furthermore, the effects of the melatonin after three months showed no change from its effects after one week of use.[27]

[edit] Fertility

A research team in Italy has found that melatonin supplementation in the evening in perimenopausal women produces an improvement in thyroid function and gonadotropin levels, as well as restoring fertility and menstruation and preventing the depression associated with the menopause.[28] One study reported that melatonin taken in the evening raised prolactin levels in six out of seven women.[29] Melatonin has been found to lower FSH levels.[30] Effects of the hormone on human reproduction remain unclear.[31]

[edit] Toxicology

Melatonin was thought to have a very low maternal toxicity in rats.[32] Newer studies, though, have found that it is toxic to photoreceptor cells in rats' retinas[33] and increases tumours in white mice.[34][35]

[edit] Headaches

Several clinical studies indicate that supplementation with melatonin is an effective preventive treatment for migraines and cluster headaches.[36][37]

[edit] Mood disorders

Melatonin has been shown to be effective in treating one form of depression and seasonal affective disorder,[38] and is being considered for bipolar and other disorders in which circadian disturbances are involved.[39] It was observed in 1985 that bipolar disorder might have elevated sensitivity to light, i.e., a greater decrease in melatonin secretion in response to light exposure at night, as a "trait marker" (a characteristic of being bipolar, which does not change with state).[40] This could be contrasted with drug-free recovered bipolar patients showing normal light sensitivity.[41]

[edit] Cancer

A systematic review of unblinded clinical trials involving a total of 643 cancer patients using melatonin found a reduced incidence of death.[42] Another clinical trial is due to be completed in 2012.[43] Modelling predicts that melatonin levels at night are reduced to 50% by exposure to a low-level incandescent bulb for only 39 minutes.[44] It has been suspected that women with the brightest bedrooms have an increased risk for breast cancer.[45] Reduced melatonin production has been proposed as a likely factor in the significantly higher cancer rates in night workers.[46]

[edit] Gallbladder stones

Melatonin presence in the gallbladder has many protective properties, such as converting cholesterol to bile, preventing oxidative stress, and increasing the mobility of gallstones from the gallbladder.[47] It also decreases the amount of cholesterol produced in the gallbladder by regulating the cholesterol that passes through the intestinal wall. In guinea pigs, melatonin administration restored normal function by reducing inflammation after induced Cholecystitis, whether administered before or after onset of inflammation.[47] Concentration of melatonin in the bile is 2–3 times higher than the otherwise very low daytime melatonin levels in the blood across many diurnal mammals, including humans.[48]

[edit] Amyotrophic lateral sclerosis

In animal models, melatonin has been shown to ameliorate glutamate-induced neuronal death, it is presumed due to its antioxidant effects. In a clinical safety study involving 31 ALS patients, high-dose rectal melatonin (300 mg/day for 2 years) was shown to be tolerated well.[49]

[edit] Obesity

Melatonin is involved in energy metabolism and body weight control in small animals. Many studies show that chronic melatonin supplementation in drinking water reduces body weight and abdominal fat in experimental animals, especially in the middle-aged rats.[50] It is interesting to note that the weight loss effect of melatonin does not require the animals to eat less and to be physically more active. A potential mechanism is that melatonin promotes the recruitment of brown adipose tissue (BAT) as well as enhances its activity.[51] This effect would raise the basal metabolic rate by stimulating thermogenesis, heat generation through uncoupling oxidative phosphorylation in mitochondria. Whether the results of animal studies can be extrapolated to human obesity is a matter of future clinical trials, since substantially active BAT has been identified in adult humans.[citation needed]

[edit] Protection from radiation

Both animal[52] and human[53][54] studies have shown melatonin to be potentially radioprotective. Moreover, it is a more efficient protector than amifostine,[55] a commonly used agent for this purpose. The mechanism of melatonin in protection against ionizing radiation is thought to involve scavenging of free radicals.[56] It is estimated that nearly 70% of biological damage caused by ionizing radiation is attributable to the free radical, especially the hydroxyl radical that attacks DNA, proteins, and cellular membranes. Melatonin has been suggested as a radioprotective agent, with the proposed advantages of being broadly protective, readily available, orally self-administered, and without major known side effects.[57]

[edit] Tinnitus

Several medical studies involving adult patients indicate that melatonin can be beneficial in the treatment of tinnitus.[58][59][60][61]

[edit] Other

Increased proliferation of cultured neural stem cells obtained from mice nervous tissue occurred when treated with melatonin.[62]

Melatonin was used to treat Periodic limb movement disorder, a common neurological condition, which, when severe, adversely affects sleep and causes excessive daytime fatigue, in a small trial conducted by Kunz D and Bes F. In this condition, the sufferer is affected by mini arousals during sleep and limb movements that occur in a frequent rhythmic fashion. This often involves leg kicking, but sometimes also involves arm movement. Those affected are often not aware of the condition, and partners are often the first to notice the condition. 7 out of the 9 participants in the trial showed significant improvement.[63]

In recent trial for use in IBS treatment, melatonin relieved some symptoms, as published in 2010[64]

[edit] Adverse effects

Melatonin appears to cause very few side-effects in the short term, up to three months, when healthy people take it at low doses. A systematic review[65] in 2006 looked specifically at efficacy and safety in two categories of melatonin usage: first, for sleep disturbances that are secondary to other diagnoses and, second, for sleep disorders such as jet lag and shift work that accompany sleep restriction.[65]

The study concluded that There is no evidence that melatonin is effective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder. There is evidence that melatonin is safe with short term use.[65]

A similar analysis[66] by the same team a year earlier on the efficacy and safety of exogenous melatonin in the management of primary sleep disorders found that: There is evidence to suggest that melatonin is safe with short-term use (3 months or less).

Some unwanted effects in some people, especially at high doses (~3 mg/day or more) may include: headaches, nausea, next-day grogginess or irritability, hormone fluctuations, vivid dreams or nightmares,[67] reduced blood flow, and hypothermia.[68]

While no large, long-term studies that might reveal side-effects have been conducted, there do exist case reports about patients having taken melatonin for months.[69]

Melatonin can cause somnolence (drowsiness), and, therefore, caution should be shown when driving, operating machinery, etc.

In individuals with auto-immune disorders, there is conflicting evidence that melatonin supplementation may either ameliorate or exacerbate symptoms due to immunomodulation.[70][71]

Individuals experiencing orthostatic intolerance, a cardiovascular condition that results in reduced blood pressure and blood flow to the brain when a person stands, may experience a worsening of symptoms when taking melatonin supplements, a study at Penn State College of Medicine's Milton S. Hershey Medical Center suggests. Melatonin can exacerbate symptoms by reducing nerve activity in those experiencing the condition, the study found.[72]

The use of melatonin derived from animal pineal tissue may carry the risk of contamination or the means of transmitting viral material. The synthetic form of this medication does not carry this risk.[4][73]

[edit] In plants

Melatonin has been identified in many plants including Feverfew (Tanacetum parthenium), and St John's wort (Hypericum perforatum).[3] It occurs in trace amounts in some foods, especially cherries to about 0.17-13.46 ng/g.[74] The physiological roles of melatonin in plants involve regulation of their response to photoperiod, defense against harsh environments, and the function of an antioxidant. The latter may be the original function of melatonin in organisms with the others being added during evolution.[75] Melatonin has been reported in foodstuffs including bananas and grapes, rice and cereals, herbs, olive oil, wine and beer. While no food has been found to elevate plasma melatonin levels in humans,[12] when other animals consume melatonin-containing food, blood levels of melatonin do increase.[11]

[edit] In animals

Many animals use the variation in duration of melatonin production each day as a seasonal clock.[76] In animals including humans[77] the profile of melatonin synthesis and secretion is affected by the variable duration of night in summer as compared to winter. The change in duration of secretion thus serves as a biological signal for the organisation of daylength-dependent (photoperiodic) seasonal functions such as reproduction, behaviour, coat growth and camouflage colouring in seasonal animals.[77] In seasonal breeders that do not have long gestation periods and that mate during longer daylight hours, the melatonin signal controls the seasonal variation in their sexual physiology, and similar physiological effects can be induced by exogenous melatonin in animals including mynah birds[78] and hamsters.[79]

[edit] In mammals

Melatonin is produced in the pineal gland, which is outside of the blood-brain barrier, acts as an endocrine hormone since it is released into the blood.[80]

Melatonin can suppress libido by inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland, especially in mammals that have a breeding season when daylight hours are long. The reproduction of long-day breeders is repressed by melatonin and the reproduction of short-day breeders is stimulated by melatonin. During the night, melatonin regulates leptin, lowering the levels; see leptin.

Light/dark information reaches the suprachiasmatic nuclei (SCN) via retinal photosensitive ganglion cells, intrinsically photosensitive photoreceptor cells, distinct from those involved in image forming (that is, these light-sensitive cells are a third type in the retina, in addition to rods and cones). These cells represent approximately 2% of the retinal ganglion cells in humans and express the photopigment melanopsin.[81] Melanopsin, often confused because of its name with the structurally unrelated hormone melatonin, is a conventional 7-transmembrane opsin protein with the usual vitamin A-like cis-retinal cofactor having peak like adsorption at 484 nm (blue light).[82] This photoperiod cue entrains the circadian rhythm, and the resultant production of specific "dark"- and "light"-induced neural and endocrine signals that regulate behavioral and physiological circadian rhythms. Melatonin is secreted in darkness in both day-active (diurnal) and night-active (nocturnal) animals.[8]

[edit] In humans

[edit] Circadian rhythm

In humans, melatonin is produced by the pineal gland, a small endocrine gland[83] located in the center of the brain but outside the blood-brain barrier. The melatonin signal forms part of the system that regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature, but it is the central nervous system (specifically the suprachiasmatic nuclei, or SCN)[83] that controls the daily cycle in most components of the paracrine and endocrine systems[84][85] rather than the melatonin signal (as was once postulated).

Infants' melatonin levels become regular in about the third month after birth, with the highest levels measured between midnight and 08:00 (8 AM).[86]

In humans, 90% of melatonin is cleared in a single passage through the liver, a small amount is excreted in urine,[17] and a small amount is found in saliva.

Human melatonin production decreases as a person ages.[87] It is believed that as children become teenagers, the nightly schedule of melatonin release is delayed, leading to later sleeping and waking times.[88]

[edit] Light dependence

Production of melatonin by the pineal gland is inhibited by light and permitted by darkness. For this reason melatonin has been called "the hormone of darkness". Its onset each evening is called the Dim-Light Melatonin Onset (DLMO).

Terman et al. devised a formulation that mimics that gradual washout (vs. the spikes in blood concentration and rapid washout associated with most over-the-counter melatonin tablets). When used several hours before sleep, the compound shifts the circadian clock earlier, thus promoting earlier sleep onset and morning awakening.[89]

It is principally blue light, around 460 to 480nm, that suppresses melatonin,[90] increasingly with increased light intensity and length of exposure. Until recent history, humans in temperate climates were exposed to few hours of (blue) daylight in the winter; their fires gave predominantly yellow light. Wearing glasses that block blue light in the hours before bedtime may avoid melatonin loss. Kayumov et al. showed that light containing only wavelengths greater than 530 nm does not suppress melatonin in bright-light conditions.[91] Use of blue-blocking goggles the last hours before bedtime has also been advised for people who need to adjust to an earlier bedtime, as melatonin promotes sleepiness.[citation needed]

[edit] Antioxidant

Besides its function as synchronizer of the biological clock, melatonin also exerts a powerful antioxidant activity. The discovery of melatonin as an antioxidant was made in 1993.[92] In many less complex life forms, this is its only known function.[93] Melatonin is an antioxidant that can easily cross cell membranes and the blood-brain barrier.[6][94] Melatonin is a direct scavenger of OH, O2−, and NO.[95] Unlike other antioxidants, melatonin does not undergo redox cycling, the ability of a molecule to undergo reduction and oxidation repeatedly. Redox cycling may allow other antioxidants (such as vitamin C) to act as pro-oxidants, counterintuitively promoting free radical formation. Melatonin, on the other hand, once oxidized, cannot be reduced to its former state because it forms several stable end-products upon reacting with free radicals. Therefore, it has been referred to as a terminal (or suicidal) antioxidant.[96]

Recent research indicates that the first metabolite of melatonin in the melatonin antioxidant pathway may be N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (or AFMK) rather than the common, excreted 6-hydroxymelatonin sulfate. AFMK alone is detectable in unicellular organisms and metazoans. A single AFMK molecule can neutralize up to 10 ROS/RNS (reactive oxygen species/reactive nitrogen species) since many of the products of the reaction/derivatives (including melatonin) are themselves antioxidants. This capacity to absorb free radicals extends at least to the quaternary metabolites of melatonin, a process referred to as "the free radical scavenging cascade." This is not true of other, conventional antioxidants.[93]

In animal models, melatonin has been demonstrated to prevent the damage to DNA by some carcinogens, stopping the mechanism by which they cause cancer.[97]

It also has been found to be effective in protecting against brain injury caused by ROS release in experimental hypoxic brain damage in newborn rats.[98] Melatonin's antioxidant activity may reduce damage caused by some types of Parkinson's disease, play a role in preventing cardiac arrhythmia and possibly increase longevity; it has been shown to increase the average life span of mice by 20% in some studies as well.[99][100][101]

[edit] Immune system

While it is known that melatonin interacts with the immune system,[102][103] the details of those interactions are unclear. There have been few trials designed to judge the effectiveness of melatonin in disease treatment. Most existing data are based on small, incomplete clinical trials. Any positive immunological effect is thought to result from melatonin acting on high affinity receptors (MT1 and MT2) expressed in immunocompetent cells. In preclinical studies, melatonin may enhance cytokine production,[104] and by doing this counteract acquired immunodeficiences. Some studies also suggest that melatonin might be useful fighting infectious disease[9] including viral, such as HIV, and bacterial infections, and potentially in the treatment of cancer.[105]

Endogenous melatonin in human lymphocytes has been related to interleukin-2 (IL-2) production and to the expression of IL-2 receptor.[106] This suggests that melatonin is involved in the clonal expansion of antigen-stimulated human T lymphocytes. In rheumatoid arthritis patients, melatonin production has been found increased when compared to age-matched healthy controls.[107]

Although it has not yet been clearly demonstrated whether melatonin increases non-specific immunity with resulting contraindication in autoimmune diseases, an increase in the production of IL-2 and IL-1 was noted in cultured splenocytes.[108]

[edit] Dreaming

Some supplemental melatonin users report an increase in vivid dreaming. Extremely high doses of melatonin (50 mg) dramatically increased REM sleep time and dream activity in both people with and without narcolepsy.[109] Many psychoactive drugs, such as cannabis and lysergic acid diethylamide (LSD), increase melatonin synthesis.[109] It has been suggested that nonpolar (lipid-soluble) indolic hallucinogenic drugs emulate melatonin activity in the awakened state and that both act on the same areas of the brain.[109]

[edit] Autism

Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis.[110]

Multiple small studies have demonstrated that 2 to 10 mg of melatonin may benefit children with ASD who have trouble falling asleep and/or maintaining sleep. A small 2011 randomized crossover trial found that the administration of melatonin, when compared to placebo, decreased sleep latency and increased total sleep time, but had no effect on the number of night time awakenings.[111] At this time, no guidelines exist for the use of melatonin in children with ASD.

[edit] Aging

Research has supported the anti-aging properties of melatonin. Younger children hit their peak melatonin production at night, and some researchers believe that the level of melatonin peaks earlier as we get older. This may explain why older adults go to bed earlier, wake up earlier, and have more sleep problems than children do.[112]

Some studies have shown that melatonin plays a crucial part in the aging process and that it may act as an anti-aging agent when taken by older adults. It has been reported in one study that while elderly people have different gene expression levels in 100 of 10,000 genes, administration of melatonin may reverse this change in gene expression thus making the genes of elderly people similar to those of younger people.[113]

One study conducted by researchers of the University of Granada’s Institute of Biotechnology found that consuming melatonin may neutralize oxidative damage and delay the neurodegenerative process of aging. When small amounts of melatonin were administered to lab mice, it reduced the oxidative damage caused by aging and delayed the inflammatory process, which in turn increased the longevity of the mice. The researchers hope these results can also be applied to humans.[114]

[edit] Melanin production

Along with melanocyte-stimulating hormone, melatonin controls the dispersion of melanin throughout melanocyte cells.[115] Melatonin controls pigmentation changes by aggregation of melanin into the melanocytes within the skin, causing the skin to change color. This is responsible for the change in skin color due to amount of sleep or the appearance of those who are sleep deprived, since melatonin also controls the circadian cycle. This interaction is also responsible for the skin color of elderly people, since melatonin production reduces with age.[citation needed]

[edit] Use as medication

A bottle of melatonin tablets

The hormone melatonin is used to treat circadian rhythm sleep disorders and some types of insomnia.

Studies have found that the use of melatonin can help entrain the circadian clock to environmental cycles and have beneficial effects for the treatment of certain forms of insomnia (2004).[116] Prolonged release melatonin has shown good results in treating insomnia in older adults (2007).[117]

A 2004 review found that melatonin significantly increased total sleep time in people suffering from sleep restriction.[17]

Other studies have found that for certain types of sleep disorders, melatonin is not effective. A 2006 review found that although it is safe for short term use (of three months or less), there is "no evidence that melatonin is effective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder."[65]

In a 2005 study, researchers concluded that while "there is some evidence to suggest that melatonin is effective in treating delayed sleep phase syndrome, ...there is evidence to suggest that melatonin is not effective in treating most primary sleep disorders with short-term use (4 weeks or less)."[118]

[edit] Dosage

Melatonin tablets/capsules often contain three to ten times the amount needed to produce physiologic nocturnal blood melatonin levels for a more rapid sleep onset. Studies suggest that smaller doses (for example 0.3 mg as opposed to 3 mg) are just as effective.[68]

Large doses of melatonin can even be counterproductive: Lewy et al.[119] provide support to the "idea that too much melatonin may spill over onto the wrong zone of the melatonin phase-response curve" (PRC). In one of their blind subjects, 0.5 mg of melatonin was effective while 20 mg was not. Solomon Labs tested initial doses of 30 and 60 milligrams and found very little efficacy even at those levels.[119][120]

[edit] History

Melatonin is related to the mechanism by which some amphibians and reptiles change the color of their skin and, indeed, it was in this connection the substance first was discovered.[121][122] As early as 1917, McCord and Allen discovered (J Exptl Zool, 1917) that extract of the pineal glands of cows lightened frog skin.[12] Dermatology professor Aaron B. Lerner and colleagues at Yale University, in the hope that a substance from the pineal might be useful in treating skin diseases, isolated the hormone from rat urine[123] and named it melatonin in 1958.[124] In the mid-70s Lynch et al. demonstrated[125] that the production of melatonin exhibits a circadian rhythm in human pineal glands. The discovery that melatonin is an antioxidant was made in 1993.[92] The first patent for its use as a low dose sleep aid was granted to Richard Wurtman at MIT in 1995.[126] Around the same time, the hormone got a lot of press as a possible treatment for many illnesses.[127] The New England Journal of Medicine editorialized in 2000: "The hype and the claims of the so-called miraculous powers of melatonin several years ago did a great disservice to a scientific field of real importance to human health. (...) Our 24-hour society, with its chaotic time cues and lack of natural light, may yet reap substantial benefits."[128]

[edit] Availability

Legal availability of melatonin varies in different countries, ranging from being available without prescription (e.g., in most of North America) to being available only on prescription or not at all (although its possession and use may not be illegal). The hormone may be administered orally, as capsules, tablets or liquid, sublingually, or as transdermal patches.

[edit] Dietary supplement

In the USA, because it is sold as a dietary supplement, sometimes combined with other ingredients, such as vitamins and herbal extracts, and not as a drug, the Food and Drug Administration (FDA) regulations that apply to medications are not applicable to melatonin.[4] However, new FDA rules required that by June 2010 all production of dietary supplements must comply with "current good manufacturing practices" (cGMP), and be manufactured with "controls that result in a consistent product free of contamination, with accurate labeling."[129] In addition, the industry has been required to report to the FDA "all serious dietary supplement related adverse events" and the FDA has, within the cGMP guidelines, recently begun enforcement of that requirement.[citation needed]

[edit] Food Products

As reported in the New York Times in May 2011,[130] melatonin is sold in grocery stores, convenience stores, and clubs in both beverage and snack forms. The FDA is considering whether these food products can continue to be sold with the label "dietary supplements". On January 13, 2010, they issued a warning letter to Innovative Beverage, creators of several beverages marketed as "relaxation drinks," stating that melatonin is not approved as a food additive because it is not generally recognized as safe.[131]

[edit] Pediatrics

While the packaging of melatonin often warns against use in children, at least one long-term study[132] does assess effectiveness and safety in children. No serious safety concerns were noted in any of the 94 cases studied by means of a structured questionnaire for the parents. With a mean follow-up time of 3.7 years, long-term medication was effective against sleep onset problems in 88% of the cases.[citation needed]

[edit] Prolonged release

Melatonin is available as a prolonged-release prescription drug, trade-name Circadin, manufactured by Neurim Pharmaceuticals. The European Medicines Agency (EMA) has approved Circadin 2 mg (prolonged-release melatonin) for patients aged 55 or over, as monotherapy for the short-term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep.[133]

[edit] See also

Wikimedia Commons has media related to: Melatonin

[edit] References

  1. ^ "Melatonin". Sleepdex. http://www.sleepdex.org/melatonin.htm. Retrieved 2011-08-17. 
  2. ^ Caniato R, Filippini R, Piovan A, Puricelli L, Borsarini A, Cappelletti EM (2003). "Melatonin in plants". Adv. Exp. Med. Biol.. Advances in Experimental Medicine and Biology 527: 593–7. doi:10.1007/978-1-4615-0135-0_68. ISBN 978-0-306-47755-3. PMID 15206778. 
  3. ^ a b Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ (2009). "Phytomelatonin: a review". J. Exp. Bot. 60 (1): 57–69. doi:10.1093/jxb/ern284. PMID 19033551. 
  4. ^ a b c Altun A, Ugur-Altun B (May 2007). "Melatonin: therapeutic and clinical utilization". Int. J. Clin. Pract. 61 (5): 835–45. doi:10.1111/j.1742-1241.2006.01191.x. PMID 17298593. 
  5. ^ Boutin JA, Audinot V, Ferry G, Delagrange P (August 2005). "Molecular tools to study melatonin pathways and actions". Trends Pharmacol. Sci. 26 (8): 412–9. doi:10.1016/j.tips.2005.06.006. PMID 15992934. 
  6. ^ a b Hardeland R (July 2005). "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine 27 (2): 119–30. doi:10.1385/ENDO:27:2:119. PMID 16217125. 
  7. ^ Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S (June 2001). "Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system". Ann. N. Y. Acad. Sci. 939: 200–15. doi:10.1111/j.1749-6632.2001.tb03627.x. PMID 11462772. 
  8. ^ a b Challet, E. (2007). "Minireview: Entrainment of the Suprachiasmatic Clockwork in Diurnal and Nocturnal Mammals". Endocrinology 148 (12): 5648–55. doi:10.1210/en.2007-0804. PMID 17901231. 
  9. ^ a b Maestroni GJ (March 2001). "The immunotherapeutic potential of melatonin". Expert Opin Investig Drugs 10 (3): 467–76. doi:10.1517/13543784.10.3.467. PMID 11227046. 
  10. ^ Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM (May 2000). "Evidence for melatonin synthesis in mouse and human bone marrow cells". J. Pineal Res. 28 (4): 193–202. doi:10.1034/j.1600-079X.2000.280401.x. PMID 10831154. 
  11. ^ a b Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, Hara M, Suzuki T, Reiter RJ (March 1995). "Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates". Biochem. Mol. Biol. Int. 35 (3): 627–34. PMID 7773197. 
  12. ^ a b c Coates, Paul M. (2005). Encyclopedia of Dietary Supplements. Marc R. Blackman, Gordon M. Cragg, Mark Levine, Joel Moss, Jeffrey D. White. CRC Press. pp. 457–466. ISBN 0824755049. http://books.google.com/?id=Sfmc-fRCj10C&pg=PA457&lpg=PA457&dq=Lerner+melatonin+history. Retrieved 2009-03-31. 
  13. ^ Ratzburg, Courtney (Undated). "Melatonin: The Myths and Facts". Vanderbilt University. http://www.vanderbilt.edu/AnS/psychology/health_psychology/melatonin.htm. Retrieved 2007-12-02. 
  14. ^ "Country Conditions for Mailing — Germany". http://pe.usps.gov/text/imm/fh_011.htm. Retrieved 2008-01-15. 
  15. ^ Lewy AJ, Sack RL, Miller LS, Hoban TM; Sack; Miller; Hoban (January 1987). "Antidepressant and circadian phase-shifting effects of light". Science 235 (4786): 352–4. Bibcode 1987Sci...235..352L. doi:10.1126/science.3798117. PMID 3798117. 
  16. ^ Uz T, Akhisaroglu M, Ahmed R, Manev H (December 2003). "The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice". Neuropsychopharmacology 28 (12): 2117–23. doi:10.1038/sj.npp.1300254. PMID 12865893. 
  17. ^ a b c Buscemi, N. et al. (2004). "Melatonin for Treatment of Sleep Disorders. Summary, Evidence Report/Technology Assessment: Number 108" (Review). U.S. Department of Health & Human Services, Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/epcsums/melatsum.htm. Retrieved 2010-05-25. 
  18. ^ H. W. Simpson (1979). "Chronobiotics: Selected Agents of Potential Value in Jet Lag and other Dyschronisms". Chronobiology: Principles and Application to Shifts in Schedules. Berlin: Springer. p. [http://books.google.co.uk/books?id=e-bZhuzXbK4C&pg=PA433&lpg=PA433&dq=chronobiotic+definition&source=bl&ots=boAbbe_1-r&sig=H0ICqtUEACE9FK6d6dwiAIHF-Mw&hl=en&ei=bkO6SpuEJ5PajQfmo_n3BQ&sa=X&oi=book_result&ct=result&resnum=7#v=onepage&q=chronobiotic%20definition&f=false. 
  19. ^ Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC (October 2005). "Phase-dependent treatment of delayed sleep phase syndrome with melatonin". Sleep 28 (10): 1271–8. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16295212 16295212]. 
  20. ^ a b Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Benbrahim-Tallaa L, Cogliano V (December 2007). "Carcinogenicity of shift-work, painting, and fire-fighting". Lancet Oncol. 8 (12): 1065–6. doi:[http://dx.doi.org/10.1016%2FS1470-2045%2807%2970373-X 10.1016/S1470-2045(07)70373-X]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/19271347 19271347]. 
  21. ^ Larson J, Jessen RE, Uz T, Arslan AD, Kurtuncu M, Imbesi M, Manev H (January 2006). "Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice". Neurosci. Lett. 393 (1): 23–6. doi:[http://dx.doi.org/10.1016%2Fj.neulet.2005.09.040 10.1016/j.neulet.2005.09.040]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16203090 16203090]. 
  22. ^ Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, Efthimiopoulos S, Robakis NK (March 1997). "Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide". J. Neurosci. 17 (5): 1683–90. PMID [http://www.ncbi.nlm.nih.gov/pubmed/9030627 9030627]. 
  23. ^ Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J (March 1998). "Inhibition of Alzheimer beta-fibrillogenesis by melatonin". J. Biol. Chem. 273 (13): 7185–8. doi:[http://dx.doi.org/10.1074%2Fjbc.273.13.7185 10.1074/jbc.273.13.7185]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/9516407 9516407]. 
  24. ^ Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y, Wang JZ (February 2005). "Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat". Sheng Li Xue Bao 57 (1): 7–12. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15719129 15719129]. 
  25. ^ Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (May 2001). "Sundowning and circadian rhythms in Alzheimer's disease". Am J Psychiatry 158 (5): 704–11. doi:[http://dx.doi.org/10.1176%2Fappi.ajp.158.5.704 10.1176/appi.ajp.158.5.704]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11329390 11329390]. 
  26. ^ Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M (July 2011). "Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial". Int J Geriatr Psychiatry 26 (7): 687–94. doi:[http://dx.doi.org/10.1002%2Fgps.2582 10.1002/gps.2582]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/20845391 20845391]. 
  27. ^ Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG (July 2003). "Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study". Eur. J. Pediatr. 162 (7–8): 554–5. doi:[http://dx.doi.org/10.1007%2Fs00431-003-1207-x 10.1007/s00431-003-1207-x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/12783318 12783318]. 
  28. ^ Bellipanni G, DI Marzo F, Blasi F, Di Marzo A (December 2005). "Effects of melatonin in perimenopausal and menopausal women: our personal experience". Ann. N. Y. Acad. Sci. 1057: 393–402. doi:[http://dx.doi.org/10.1196%2Fannals.1356.030 10.1196/annals.1356.030]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16399909 16399909]. 
  29. ^ Terzolo M, Revelli A, Guidetti D, Piovesan A, Cassoni P, Paccotti P, Angeli A, Massobrio M (August 1993). "Evening administration of melatonin enhances the pulsatile secretion of prolactin but not of LH and TSH in normally cycling women". Clin. Endocrinol. (Oxf) 39 (2): 185–91. doi:[http://dx.doi.org/10.1111%2Fj.1365-2265.1993.tb01772.x 10.1111/j.1365-2265.1993.tb01772.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/8370131 8370131]. 
  30. ^ . PMID [http://www.ncbi.nlm.nih.gov/pubmed/16921343 16921343]. 
  31. ^ . PMID [http://www.ncbi.nlm.nih.gov/pubmed/19905996 19905996]. 
  32. ^ Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C (August 1999). "Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats". Toxicol. Sci. 50 (2): 271–9. doi:[http://dx.doi.org/10.1093%2Ftoxsci%2F50.2.271 10.1093/toxsci/50.2.271]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/10478864 10478864]. 
  33. ^ . PMID [http://www.ncbi.nlm.nih.gov/pubmed/18078931 18078931]. 
  34. ^ . PMID [http://www.ncbi.nlm.nih.gov/pubmed/11445596 11445596]. 
  35. ^ {{cite web |url=http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm201435.htm |title=Warning Letter |author=Reynaldo R. Rodriguez |publisher=[[U.S. Food and Drug Administration }}
  36. ^ Dodick DW, Capobianco DJ (February 2001). "Treatment and management of cluster headache". Curr Pain Headache Rep 5 (1): 83–91. doi:[http://dx.doi.org/10.1007%2Fs11916-001-0015-0 10.1007/s11916-001-0015-0]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11252143 11252143]. 
  37. ^ Gagnier JJ (August 2001). "The therapeutic potential of melatonin in migraines and other headache types". Altern Med Rev 6 (4): 383–9. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11578254 11578254]. 
  38. ^ [http://www.nimh.nih.gov/science-news/2006/properly-timed-light-melatonin-lift-winter-depression-by-syncing-rhythms.shtml "Properly Timed Light, Melatonin Lift Winter Depression By Syncing Rhythms"]. National Institute of Mental Health. 2006-05-01. http://www.nimh.nih.gov/science-news/2006/properly-timed-light-melatonin-lift-winter-depression-by-syncing-rhythms.shtml. Retrieved 2011-08-17. 
  39. ^ Bhattacharjee Y (September 2007). "Psychiatric research. Is internal timing key to mental health?". Science 317 (5844): 1488–90. doi:[http://dx.doi.org/10.1126%2Fscience.317.5844.1488 10.1126/science.317.5844.1488]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17872420 17872420]. 
  40. ^ Lewy AJ, Nurnberger JI, Wehr TA, Pack D, Becker LE, Powell RL, Newsome DA (June 1985). "Supersensitivity to light: possible trait marker for manic-depressive illness". Am J Psychiatry 142 (6): 725–7. PMID [http://www.ncbi.nlm.nih.gov/pubmed/4003592 4003592]. 
  41. ^ Whalley LJ, Perini T, Shering A, Bennie J (July 1991). "Melatonin response to bright light in recovered, drug-free, bipolar patients". Psychiatry Res 38 (1): 13–9. doi:[http://dx.doi.org/10.1016%2F0165-1781%2891%2990048-T 10.1016/0165-1781(91)90048-T]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/1658841 1658841]. 
  42. ^ Mills E, Wu P, Seely D, Guyatt G (November 2005). "Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis". J. Pineal Res. 39 (4): 360–6. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2005.00258.x 10.1111/j.1600-079X.2005.00258.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16207291 16207291]. 
  43. ^ "Melatonin as an anticancer agent with and without chemotherapy: systematic review and meta-analysis [item 3]." Canadian College of Naturopathic Medicine. [http://www.ccnm.edu/?q=current_research Current Research].
  44. ^ Pauley SM. (2004). "Lighting for the human circadian clock: recent research indicates lighting has become a public health issue". Medical Hypotheses 63 (4): 588-96. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15325001 15325001]. 
  45. ^ Navara KJ, Nelson RJ (October 2007). "The dark side of light at night: physiological, epidemiological, and ecological consequences". J. Pineal Res. 43 (3): 215–24. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2007.00473.x 10.1111/j.1600-079X.2007.00473.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17803517 17803517]. 
  46. ^ Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE (June 2004). "Epidemiology of urinary melatonin in women and its relation to other hormones and night work". Cancer Epidemiol. Biomarkers Prev. 13 (6): 936–43. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15184249 15184249]. 
  47. ^ a b Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, Tan DX, Reiter RJ (October 2008). "Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review". Dig. Dis. Sci. 53 (10): 2592–603. doi:[http://dx.doi.org/10.1007%2Fs10620-007-0195-5 10.1007/s10620-007-0195-5]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/18338264 18338264]. 
  48. ^ Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ (October 1999). "High physiological levels of melatonin in the bile of mammals". Life Sci. 65 (23): 2523–9. doi:[http://dx.doi.org/10.1016%2FS0024-3205%2899%2900519-6 10.1016/S0024-3205(99)00519-6]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/10622237 10622237]. 
  49. ^ Weishaupt JH, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Hüther G, Schneider A, Bach A, Sirén AL, Hardeland R, Bähr M, Nave KA, Ehrenreich H (November 2006). "Reduced oxidative damage in ALS by high-dose enteral melatonin treatment". J. Pineal Res. 41 (4): 313–23. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2006.00377.x 10.1111/j.1600-079X.2006.00377.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17014688 17014688]. 
  50. ^ Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, Rasmussen DD (February 2000). "Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat". Endocrinology 141 (2): 487–97. doi:[http://dx.doi.org/10.1210%2Fen.141.2.487 10.1210/en.141.2.487]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/10650927 10650927]. 
  51. ^ Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ (March 2011). "Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity". Obes Rev 12 (3): 167–88. doi:[http://dx.doi.org/10.1111%2Fj.1467-789X.2010.00756.x 10.1111/j.1467-789X.2010.00756.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/20557470 20557470]. 
  52. ^ Vijayalaxmi, Meltz ML, Reiter RJ, Herman TS, Kumar KS (March 1999). "Melatonin and protection from whole-body irradiation: survival studies in mice". Mutat. Res. 425 (1): 21–7. doi:[http://dx.doi.org/10.1016%2FS0027-5107%2898%2900246-2 10.1016/S0027-5107(98)00246-2]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/10082913 10082913]. 
  53. ^ Vijayalaxmi, Reiter RJ, Herman TS, Meltz ML (December 1996). "Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers". Mutat. Res. 371 (3–4): 221–8. doi:[http://dx.doi.org/10.1016%2FS0165-1218%2896%2990110-X 10.1016/S0165-1218(96)90110-X]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/9008723 9008723]. 
  54. ^ Vijayalaxmi, Reiter RJ, Herman TS, Meltz ML (February 1998). "Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes". Mutat. Res. 397 (2): 203–8. doi:[http://dx.doi.org/10.1016%2FS0027-5107%2897%2900211-X 10.1016/S0027-5107(97)00211-X]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/9541644 9541644]. 
  55. ^ Topkan E, Tufan H, Yavuz AA, Bacanli D, Onal C, Kosdak S, Yavuz MN (October 2008). "Comparison of the protective effects of melatonin and amifostine on radiation-induced epiphyseal injury". Int. J. Radiat. Biol. 84 (10): 796–802. doi:[http://dx.doi.org/10.1080%2F09553000802389678 10.1080/09553000802389678]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/18979313 18979313]. 
  56. ^ Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (January 2007). "One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?". J. Pineal Res. 42 (1): 28–42. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2006.00407.x 10.1111/j.1600-079X.2006.00407.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17198536 17198536]. 
  57. ^ Shirazi A, Ghobadi G, Ghazi-Khansari M (July 2007). "A radiobiological review on melatonin: a novel radioprotector". J. Radiat. Res. 48 (4): 263–72. doi:[http://dx.doi.org/10.1269%2Fjrr.06070 10.1269/jrr.06070]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17641465 17641465]. 
  58. ^ Hurtuk A, Dome C, Holloman CH, Wolfe K, Welling DB, Dodson EE, Jacob A (July 2011). "Melatonin: can it stop the ringing?". Ann. Otol. Rhinol. Laryngol. 120 (7): 433–40. PMID [http://www.ncbi.nlm.nih.gov/pubmed/21859051 21859051]. 
  59. ^ Megwalu UC, Finnell JE, Piccirillo JF (February 2006). "The effects of melatonin on tinnitus and sleep". Otolaryngol Head Neck Surg 134 (2): 210–3. doi:[http://dx.doi.org/10.1016%2Fj.otohns.2005.10.007 10.1016/j.otohns.2005.10.007]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16455366 16455366]. 
  60. ^ Rosenberg SI, Silverstein H, Rowan PT, Olds MJ (March 1998). "Effect of melatonin on tinnitus". Laryngoscope 108 (3): 305–10. doi:[http://dx.doi.org/10.1097%2F00005537-199803000-00001 10.1097/00005537-199803000-00001]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/9504599 9504599]. 
  61. ^ Pirodda A, Raimondi MC, Ferri GG (August 2010). "Exploring the reasons why melatonin can improve tinnitus". Med. Hypotheses 75 (2): 190–1. doi:[http://dx.doi.org/10.1016%2Fj.mehy.2010.02.018 10.1016/j.mehy.2010.02.018]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/20207491 20207491]. 
  62. ^ Sotthibundhu A, Phansuwan-Pujito P, Govitrapong P (October 2010). "Melatonin increases proliferation of cultured neural stem cells obtained from adult mouse subventricular zone". J. Pineal Res. 49 (3): 291–300. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2010.00794.x 10.1111/j.1600-079X.2010.00794.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/20663047 20663047]. 
  63. ^ Kunz D, Bes F (March 2001). "Exogenous melatonin in periodic limb movement disorder: an open clinical trial and a hypothesis". Sleep 24 (2): 183–7. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11247054 11247054]. 
  64. ^ Basu P.P., Pacana T., Shah N., Hampole H., Krishnaswamy N., Rayapudi K. "Role of melatonin in colonic motility in irritable bowel syndrome - Constipation MIMI-C-a double blinded randomized placebocontrol clinical trial". in <Please add first missing authors to populate metadata.> (2010). "Poster Presentations". Neurogastroenterology & Motility 22: 23–90. doi:[http://dx.doi.org/10.1111%2Fj.1365-2982.2010.01549.x 10.1111/j.1365-2982.2010.01549.x]. 
  65. ^ a b c d Buscemi, N.; Vandermeer, B; Hooton, N; Pandya, R; Tjosvold, L; Hartling, L; Vohra, S; Klassen, TP et al (2006). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1370968 "Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis"]. BMJ 332 (7538): 385–93. doi:[http://dx.doi.org/10.1136%2Fbmj.38731.532766.F6 10.1136/bmj.38731.532766.F6]. PMC [http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=1370968 1370968]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16473858 16473858]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1370968. 
  66. ^ Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S (December 2005). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1490287 "The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis"]. J Gen Intern Med 20 (12): 1151–8. doi:[http://dx.doi.org/10.1111%2Fj.1525-1497.2005.0243.x 10.1111/j.1525-1497.2005.0243.x]. PMC [http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=1490287 1490287]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16423108 16423108]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1490287. 
  67. ^ Brent Bauer, M.D.. [http://www.mayoclinic.com/health/melatonin-side-effects/AN01717 "Melatonin side effects: What are the risks?"]. Mayo Clinic. http://www.mayoclinic.com/health/melatonin-side-effects/AN01717. Retrieved 2011-08-17. 
  68. ^ a b Zhdanova, I. V. (2001). "Melatonin Treatment for Age-Related Insomnia". Journal of Clinical Endocrinology & Metabolism 86 (10): 4727–30. doi:[http://dx.doi.org/10.1210%2Fjc.86.10.4727 10.1210/jc.86.10.4727]. 
  69. ^ Sack RL, Brandes RW, Kendall AR, Lewy AJ (October 2000). "Entrainment of free-running circadian rhythms by melatonin in blind people". N. Engl. J. Med. 343 (15): 1070–7. doi:[http://dx.doi.org/10.1056%2FNEJM200010123431503 10.1056/NEJM200010123431503]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11027741 11027741]. 
  70. ^ Morera, AL; Henry, M; De La Varga, M (2001). "Safety in melatonin use". Actas espanolas de psiquiatria 29 (5): 334–7. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11602091 11602091]. 
  71. ^ Terry PD, Villinger F, Bubenik GA, Sitaraman SV (January 2009). "Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research". Inflamm. Bowel Dis. 15 (1): 134–40. doi:[http://dx.doi.org/10.1002%2Fibd.20527 10.1002/ibd.20527]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/18626968 18626968]. 
  72. ^ [http://www.hmc.psu.edu/news/pr/2003/sept/Ray_melatonin.doc "Study Shows Melatonin Supplements May Make Standing A Hazard For The Cardiovascular-Challenged"] (DOC) (Press release). Penn State College of Medicine, Milton S. Hershey Medical Center. September 2003. http://www.hmc.psu.edu/news/pr/2003/sept/Ray_melatonin.doc. Retrieved 2006-07-21.  (MS Word Format)
  73. ^ [http://www.drugs.com/melatonin.html "Melatonin"]. Drugs.com. http://www.drugs.com/melatonin.html. Retrieved 2011-08-17. 
  74. ^ Burkhardt, Susanne; Tan, Dun Xian; Manchester, Lucien C.; Hardeland, RüDiger; Reiter, Russel J. (2001). "Detection and Quantification of the Antioxidant Melatonin in Montmorency and Balaton Tart Cherries (Prunus cerasus)". Journal of Agricultural and Food Chemistry 49 (10): 4898–902. doi:[http://dx.doi.org/10.1021%2Fjf010321 10.1021/jf010321]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11600041 11600041]. 
  75. ^ Tan, Dun-Xian; Hardeland, RüDiger; Manchester, Lucien C.; Paredes, Sergio D.; Korkmaz, Ahmet; Sainz, Rosa M.; Mayo, Juan C.; Fuentes-Broto, Lorena et al (2009). "The changing biological roles of melatonin during evolution: from an antioxidant to signals of darkness, sexual selection and fitness". Biological Reviews: 607–23. doi:[http://dx.doi.org/10.1111%2Fj.1469-185X.2009.00118.x 10.1111/j.1469-185X.2009.00118.x]. 
  76. ^ Lincoln, G.; Andersson, H; Loudon, A (2003). "Clock genes in calendar cells as the basis of annual timekeeping in mammals--a unifying hypothesis". Journal of Endocrinology 179 (1): 1–13. doi:[http://dx.doi.org/10.1677%2Fjoe.0.1790001 10.1677/joe.0.1790001]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/14529560 14529560]. 
  77. ^ a b Arendt, Josephine; Skene, Debra Jean (2005). "Melatonin as a chronobiotic". Sleep Medicine Reviews 9 (1): 25–39. doi:[http://dx.doi.org/10.1016%2Fj.smrv.2004.05.002 10.1016/j.smrv.2004.05.002]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15649736 15649736]. "Exogenous melatonin has acute sleepiness-inducing and temperature-lowering effects during 'biological daytime', and when suitably timed (it is most effective around dusk and dawn) it will shift the phase of the human circadian clock (sleep, endogenous melatonin, core body temperature, cortisol) to earlier (advance phase shift) or later (delay phase shift) times." 
  78. ^ Chaturvedi, CM (1984). [http://www.publish.csiro.au/paper/ZO9840803.htm "Effect of Melatonin on the Adrenl and Gonad of the Common Mynah Acridtheres tristis"]. Australian Journal of Zoology 32 (6): 803–9. doi:[http://dx.doi.org/10.1071%2FZO9840803 10.1071/ZO9840803]. http://www.publish.csiro.au/paper/ZO9840803.htm. 
  79. ^ Chen, H.J. (1981). "Spontaneous and Melatonin-Induced Testicular Regression in Male Golden Hamsters: Augmented Sensitivity of the Old Male to Melatonin Inhibition". Neuroendocrinology 33 (1): 43–6. doi:[http://dx.doi.org/10.1159%2F000123198 10.1159/000123198]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/7254478 7254478]. 
  80. ^ Kaur C, Ling EA (2008). "Antioxidants and neuroprotection in the adult and developing central nervous system". Curr. Med. Chem. 15 (29): 3068–80. doi:[http://dx.doi.org/10.2174%2F092986708786848640 10.2174/092986708786848640]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/19075654 19075654]. 
  81. ^ Nayak, S. Kumar; Jegla, T.; Panda, S. (2006). "Role of a novel photopigment, melanopsin, in behavioral adaptation to light". Cellular and Molecular Life Sciences 64 (2): 144–54. doi:[http://dx.doi.org/10.1007%2Fs00018-006-5581-1 10.1007/s00018-006-5581-1]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17160354 17160354]. 
  82. ^ Roberts, Joan E. (2005). "Update on the Positive Effects of Light in Humans". Photochemistry and Photobiology: 490–2. doi:[http://dx.doi.org/10.1562%2F2004-12-02-IR-391 10.1562/2004-12-02-IR-391]. 
  83. ^ a b Reiter, R. J. Pineal Melatonin: Cell Biology of Its Synthesis and of Its Physiological Interactions Endocr. Rev. 1991, 12, 151-180.
  84. ^ Richardson, GS (2005). "The human circadian system in normal and disordered sleep". The Journal of clinical psychiatry 66 Suppl 9: 3–9; quiz 42–3. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16336035 16336035]. 
  85. ^ Perreau-Lenz, StéPhanie; Pévet, Paul; Buijs, Ruud M.; Kalsbeek, Andries (2004). "The Biological Clock: The Bodyguard of Temporal Homeostasis". Chronobiology International 21 (1): 1–25. doi:[http://dx.doi.org/10.1081%2FCBI-120027984 10.1081/CBI-120027984]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15129821 15129821]. 
  86. ^ Ardura, Julio; Gutierrez, Regina; Andres, Jesus; Agapito, Teresa (2003). "Emergence and Evolution of the Circadian Rhythm of Melatonin in Children". Hormone Research 59 (2): 66–72. doi:[http://dx.doi.org/10.1159%2F000068571 10.1159/000068571]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/12589109 12589109]. 
  87. ^ Sack, RL; Lewy, AJ; Erb, DL; Vollmer, WM; Singer, CM (1986). "Human melatonin production decreases with age". Journal of pineal research 3 (4): 379–88. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.1986.tb00760.x 10.1111/j.1600-079X.1986.tb00760.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/3783419 3783419]. 
  88. ^ Gavin, Mary L.; Scavina, Mena T. (2009). [http://kidshealth.org/teen/your_body/take_care/how_much_sleep.html "Why Aren't Teens Getting Enough Sleep?"]. How Much Sleep Do I Need?. http://kidshealth.org/teen/your_body/take_care/how_much_sleep.html. 
  89. ^ Wirz-Justice, A; Benedetti, F; Terman, M (2009). Chronotherapeutics for Affective Disorders: A Clinician’s Manual for Light and Wake Therapy. Basel: Karger. p. 71. ISBN 978-3-8055-9120-1. 
  90. ^ Brainard, GC; Hanifin, JP; Greeson, JM; Byrne, B; Glickman, G; Gerner, E; Rollag, MD (2001). "Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor". The Journal of neuroscience : the official journal of the Society for Neuroscience 21 (16): 6405–12. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11487664 11487664]. 
  91. ^ Kayumov, L. (2005). "Blocking Low-Wavelength Light Prevents Nocturnal Melatonin Suppression with No Adverse Effect on Performance during Simulated Shift Work". Journal of Clinical Endocrinology & Metabolism 90 (5): 2755–61. doi:[http://dx.doi.org/10.1210%2Fjc.2004-2062 10.1210/jc.2004-2062]. 
  92. ^ a b Tan, D. X.; Chen, L. D.; Poeggeler, B.; Manchester, L. C.; Reiter, R. J. (1993). "Melatonin: a potent, endogenous hydroxyl radical scavenger". Endocrine J 1: 57–60. 
  93. ^ a b Tan, Dun-Xian; Manchester, Lucien C.; Terron, Maria P.; Flores, Luis J.; Reiter, Russel J. (2007). "One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species?". Journal of Pineal Research 42 (1): 28–42. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2006.00407.x 10.1111/j.1600-079X.2006.00407.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17198536 17198536]. 
  94. ^ Reiter RJ, Manchester LC, Tan DX (September 2010). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3001213 "Neurotoxins: free radical mechanisms and melatonin protection"]. Curr Neuropharmacol 8 (3): 194–210. doi:[http://dx.doi.org/10.2174%2F157015910792246236 10.2174/157015910792246236]. PMC [http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=3001213 3001213]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/21358970 21358970]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3001213. 
  95. ^ Poeggeler, Burkhard; Saarela, Seppo; Reiter, Russel J.; Tan, DUN-Xian; Chen, LI-DUN; Manchester, Lucien C.; Barlow-Walden, Lornell R. (2006). "Melatonin-A Highly Potent Endogenous Radical Scavenger and Electron Donor: New Aspects of the Oxidation Chemistry of this Indole Accessed in vitroa". Annals of the New York Academy of Sciences 738: 419–20. doi:[http://dx.doi.org/10.1111%2Fj.1749-6632.1994.tb21831.x 10.1111/j.1749-6632.1994.tb21831.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/7832450 7832450]. 
  96. ^ Tan, Dun-Xian; Manchester, Lucien C.; Reiter, Russel J.; Qi, Wen-Bo; Karbownik, Malgorzata; Calvo, Juan R. (2000). "Significance of Melatonin in Antioxidative Defense System: Reactions and Products". Neurosignals 9 (3–4): 137–59. doi:[http://dx.doi.org/10.1159%2F000014635 10.1159/000014635]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/10899700 10899700]. 
  97. ^ Karbownik, M; Reiter, Russel J.; Cabrera, Javier; Garcia, Joaquin J. (2001). "Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage". Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 474: 87–92. doi:[http://dx.doi.org/10.1016%2FS0027-5107%2800%2900164-0 10.1016/S0027-5107(00)00164-0]. 
  98. ^ Tutunculer, Filiz; Eskiocak, Sevgi; Basaran, Umit Nusret; Ekuklu, Galip; Ayvaz, Suleyman; Vatansever, Ulfet (2005). "The protective role of melatonin in experimental hypoxic brain damage". Pediatrics International 47 (4): 434–9. doi:[http://dx.doi.org/10.1111%2Fj.1442-200x.2005.02085.x 10.1111/j.1442-200x.2005.02085.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16091083 16091083]. 
  99. ^ Ward Dean, John Morgenthaler, Steven William Fowkes (1993). Smart Drugs II: The Next Generation : New Drugs and Nutrients to Improve Your Memory and Increase Your Intelligence (Smart Drug Series, V. 2). Smart Publications. ISBN 0-9627418-7-6. [page needed]
  100. ^ Anisimov, V; Alimova, IN; Baturin, DA; Popovich, IG; Zabezhinski, MA; Rosenfeld, SV; Manton, KG; Semenchenko, AV et al (2003). "Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice". Experimental Gerontology 38 (4): 449–61. doi:[http://dx.doi.org/10.1016%2FS0531-5565%2802%2900240-1 10.1016/S0531-5565(02)00240-1]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/12670632 12670632]. 
  101. ^ Oaknin-Bendahan, Sol; Anis, Yossi; Nir, Isaac; Zisapel, Nava (1995). "Effects of long-term administration of melatonin and a putative antagonist on the ageing rat". NeuroReport 6 (5): 785–8. doi:[http://dx.doi.org/10.1097%2F00001756-199503270-00020 10.1097/00001756-199503270-00020]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/7605949 7605949]. 
  102. ^ Carrillo-Vico, Antonio; Guerrero, Juan M.; Lardone, Patricia J.; Reiter, Russel J. (2005). "A Review of the Multiple Actions of Melatonin on the Immune System". Endocrine 27 (2): 189–200. doi:[http://dx.doi.org/10.1385%2FENDO%3A27%3A2%3A189 10.1385/ENDO:27:2:189]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16217132 16217132]. 
  103. ^ Arushanian, EB; Beĭer, EV (2002). "Immunotropic properties of pineal melatonin". Eksperimental'naia i klinicheskaia farmakologiia 65 (5): 73–80. PMID [http://www.ncbi.nlm.nih.gov/pubmed/12596522 12596522]. 
  104. ^ Carrillo-Vico, A; Reiter, RJ; Lardone, PJ; Herrera, JL; Fernández-Montesinos, R; Guerrero, JM; Pozo, D (2006). "The modulatory role of melatonin on immune responsiveness". Current opinion in investigational drugs (London, England : 2000) 7 (5): 423–31. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16729718 16729718]. 
  105. ^ Maestroni, GJ (1999). "Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer". Advances in experimental medicine and biology. Advances in Experimental Medicine and Biology 467: 217–26. doi:[http://dx.doi.org/10.1007%2F978-1-4615-4709-9_28 10.1007/978-1-4615-4709-9_28]. ISBN 978-0-306-46204-7. PMID [http://www.ncbi.nlm.nih.gov/pubmed/10721059 10721059]. 
  106. ^ Carrillo-Vico, A. (2004). "Human Lymphocyte-Synthesized Melatonin Is Involved in the Regulation of the Interleukin-2/Interleukin-2 Receptor System". Journal of Clinical Endocrinology & Metabolism 90 (2): 992–1000. doi:[http://dx.doi.org/10.1210%2Fjc.2004-1429 10.1210/jc.2004-1429]. 
  107. ^ Cutolo, M; Maestroni, GJ (2005). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1755599 "The melatonin-cytokine connection in rheumatoid arthritis"]. Annals of the Rheumatic Diseases 64 (8): 1109–11. doi:[http://dx.doi.org/10.1136%2Fard.2005.038588 10.1136/ard.2005.038588]. PMC [http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=1755599 1755599]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16014678 16014678]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1755599. 
  108. ^ Arias, J; Melean, E; Valero, N; Pons, H; Chacín-Bonilla, L; Larreal, Y; Bonilla, E (2003). "Effect of melatonin on lymphocyte proliferation and production of interleukin-2 (IL-2) and interleukin-1 beta (IL-1 beta) in mice splenocytes". Investigacion clinica 44 (1): 41–50. PMID [http://www.ncbi.nlm.nih.gov/pubmed/12703182 12703182]. 
  109. ^ a b c Lewis, Alan (1999). Melatonin and the Biological Clock. McGraw-Hill. p. 23. ISBN 0-87983-734-9. 
  110. ^ Melke, J; Goubran Botros, H; Chaste, P; Betancur, C; Nygren, G; Anckarsäter, H; Rastam, M; Ståhlberg, O et al (2007). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2199264 "Abnormal melatonin synthesis in autism spectrum disorders"]. Molecular Psychiatry 13 (1): 90–8. doi:[http://dx.doi.org/10.1038%2Fsj.mp.4002016 10.1038/sj.mp.4002016]. PMC [http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=2199264 2199264]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17505466 17505466]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2199264. 
  111. ^ Wright, Barry; Sims, David; Smart, Siobhan; Alwazeer, Ahmed; Alderson-Day, Ben; Allgar, Victoria; Whitton, Clare; Tomlinson, Heather et al (2010). "Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial". Journal of Autism and Developmental Disorders 41 (2): 175–84. doi:[http://dx.doi.org/10.1007%2Fs10803-010-1036-5 10.1007/s10803-010-1036-5]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/20535539 20535539]. 
  112. ^ University of Maryland Medical Center. “Melatonin.” 2011. http://www.umm.edu/altmed/articles/melatonin-000315.htm
  113. ^ Sharman, Edward H.; Sharman, Kaizhi G.; Ge, Yuan-Wen; Lahiri, Debomoy K.; Bondy, Stephen C. (2004). "Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin". Journal of Pineal Research 36 (3): 165–70. doi:[http://dx.doi.org/10.1046%2Fj.1600-079X.2003.00112.x 10.1046/j.1600-079X.2003.00112.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15009506 15009506]. 
  114. ^ Acuna-Castroviejo, Dario; Martin, Miguel; MacIas, Manuel; Escames, Germaine; Leon, Josefa; Khaldy, Huda; Reiter, Russel J. (2001). "Melatonin, mitochondria, and cellular bioenergetics". Journal of Pineal Research 30 (2): 65–74. doi:[http://dx.doi.org/10.1034%2Fj.1600-079X.2001.300201.x 10.1034/j.1600-079X.2001.300201.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11270481 11270481]. [http://www.sciencedaily.com/releases/2007/04/070424062819.htm Lay summary] – Science Daily (April 24, 2007). 
  115. ^ OxfordUniversity. "A Dictionary of Science: Fifth Edition". Oxford University Press, p.513
  116. ^ Turek, F; Gillette, M (2004). "Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists". Sleep Medicine 5 (6): 523–32. doi:[http://dx.doi.org/10.1016%2Fj.sleep.2004.07.009 10.1016/j.sleep.2004.07.009]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15511698 15511698]. 
  117. ^ Wade, Alan G; Ford, Ian; Crawford, Gordon; McMahon, Alex D; Nir, Tali; Laudon, Moshe; Zisapel, Nava (2007). "Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes". Current Medical Research and Opinion 23 (10): 2597–605. doi:[http://dx.doi.org/10.1185%2F030079907X233098 10.1185/030079907X233098]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17875243 17875243]. 
  118. ^ Buscemi, Nina; Vandermeer, Ben; Hooton, Nicola; Pandya, Rena; Tjosvold, Lisa; Hartling, Lisa; Baker, Glen; Klassen, Terry P. et al (2005). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1490287 "The Efficacy and Safety of Exogenous Melatonin for Primary Sleep Disorders. A Meta-Analysis"]. Journal of General Internal Medicine 20 (12): 1151–8. doi:[http://dx.doi.org/10.1111%2Fj.1525-1497.2005.0243.x 10.1111/j.1525-1497.2005.0243.x]. PMC [http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=1490287 1490287]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16423108 16423108]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1490287. 
  119. ^ a b Lewy, Alfred J.; Emens, Jonathan S.; Sack, Robert L.; Hasler, Brant P.; Bernert, Rebecca A. (2002). "Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period". Chronobiology International 19 (3): 649–58. doi:[http://dx.doi.org/10.1081%2FCBI-120004546 10.1081/CBI-120004546]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/12069043 12069043]. 
  120. ^ Sack, Robert L.; Brandes, Richard W.; Kendall, Adam R.; Lewy, Alfred J. (2000). "Entrainment of Free-Running Circadian Rhythms by Melatonin in Blind People". New England Journal of Medicine 343 (15): 1070–77. doi:[http://dx.doi.org/10.1056%2FNEJM200010123431503 10.1056/NEJM200010123431503]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11027741 11027741]. 
  121. ^ Filadelfi, Ana Maria Caliman; Castrucci, Ana Maria de Lauro (1996). "Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates". Journal of Pineal Research 20 (4): 175–86. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.1996.tb00256.x 10.1111/j.1600-079X.1996.tb00256.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/8836950 8836950]. 
  122. ^ Sugden, David; Davidson, Kathryn; Hough, Kate A.; Teh, Muy-Teck (2004). "Melatonin, Melatonin Receptors and Melanophores: A Moving Story". Pigment Cell Research 17 (5): 454–60. doi:[http://dx.doi.org/10.1111%2Fj.1600-0749.2004.00185.x 10.1111/j.1600-0749.2004.00185.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15357831 15357831]. 
  123. ^ Yu, H. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications; 1992; , pp 550.
  124. ^ Lerner, AB; Case, JD; Takahashi, Y (1960). "Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands". The Journal of biological chemistry 235: 1992–7. PMID [http://www.ncbi.nlm.nih.gov/pubmed/14415935 14415935]. 
  125. ^ Lynch, H.; Wurtman, R.; Moskowitz, M.; Archer, M.; Ho, M. (1975). "Daily rhythm in human urinary melatonin". Science 187 (4172): 169–71. doi:[http://dx.doi.org/10.1126%2Fscience.1167425 10.1126/science.1167425]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/1167425 1167425]. 
  126. ^ [http://www.patentgenius.com/patent/5449683.html Methods of inducing sleep using melatonin: US Patent # 5449683] retrieved 8 January 2012
  127. ^ Arendt, J. (2005). "Melatonin: Characteristics, Concerns, and Prospects". Journal of Biological Rhythms 20 (4): 291–303. doi:[http://dx.doi.org/10.1177%2F0748730405277492 10.1177/0748730405277492]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/16077149 16077149]. "There is very little evidence in the short term for toxicity or undesirable effects in humans. The extraordinary “hype” of the miraculous powers of melatonin in the recent past did a disservice to acceptance of its genuine benefits." 
  128. ^ Arendt, Josephine (2000). "Melatonin, Circadian Rhythms, and Sleep". New England Journal of Medicine 343 (15): 1114–6. doi:[http://dx.doi.org/10.1056%2FNEJM200010123431510 10.1056/NEJM200010123431510]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/11027748 11027748]. 
  129. ^ [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108938.htm "FDA Issues Dietary Supplements Final Rule"] (Press release). U.S. Food and Drug Administration. 2007-06-22. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108938.htm. Retrieved 2009-08-04. 
  130. ^ Catherine Saint Louis (14 May 2011). [http://www.nytimes.com/2011/05/15/us/15lazycakes.html?_r=1&scp=1&sq=lazy%20cakes&st=cse "Dessert, Laid-Back and Legal"]. New York Times. http://www.nytimes.com/2011/05/15/us/15lazycakes.html?_r=1&scp=1&sq=lazy%20cakes&st=cse. 
  131. ^ Reynaldo R. Rodriguez (13 January 2010). [http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm201435.htm "Warning Letter"]. U.S. Food and Drug Administration. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2010/ucm201435.htm. 
  132. ^ Hoebert, Michel; Van Der Heijden, Kristiaan B.; Van Geijlswijk, Ingeborg M.; Smits, Marcel G. (2009). "Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia". Journal of Pineal Research 47 (1): 1–7. doi:[http://dx.doi.org/10.1111%2Fj.1600-079X.2009.00681.x 10.1111/j.1600-079X.2009.00681.x]. PMID [http://www.ncbi.nlm.nih.gov/pubmed/19486273 19486273]. 
  133. ^ [http://www.medicalnewstoday.com/articles/69195.php Medical News Today] Circadin (Prolonged-Release Melatonin) For Primary Insomnia Recommended For Approval In The EU (27 Apr 2007)

[edit] External links
Amino acids
Endocannabinoids
Gasotransmitters
Monoamines
Purines

Adenosine · ADP · AMP · ATP
Trace amines
Others
Types
Vitamins and
"minerals" (chemical elements)
Other common ingredients
Related articles
GABAA agonists/PAMs
Barbiturates: Allobarbital • Amobarbital • Aprobarbital • Barbital • Butabarbital • Butobarbital • Cyclobarbital • Ethallobarbital • Heptabarb • Hexobarbital • Mephobarbital • Methohexital • Pentobarbital • Phenobarbital • Proxibarbal • Reposal • Secobarbital • Talbutal • Thiamylal • Thiopental • Vinbarbital • Vinylbital
Benzodiazepines: Brotizolam • Clonazepam • Cinolazepam • Climazolam • Doxefazepam • Estazolam • Flunitrazepam • Flurazepam • Flutoprazepam • Haloxazolam • Loprazolam • Lorazepam •Lormetazepam • Midazolam • Nimetazepam • Nitrazepam • Quazepam • Temazepam • Triazolam
Carbamates: Carisoprodol • Ethinamate • Hexapropymate • Meprobamate • Methocarbamol • Procymate • Tybamate
Neuroactive Steroids: Acebrochol • Allopregnanolone • Alphadolone • Alphaxolone • Eltanolone • Ganaxolone • Hydroxydione • Minaxolone • Org 20599 • Org 21465 • Tetrahydrodeoxycorticosterone
Nonbenzodiazepines: CL-218,872 • Eszopiclone • Indiplon • JM-1232 • Lirequinil • Necopidem • Pazinaclone • ROD-188 • Saripidem • Suproclone • Suriclone • SX-3228 • U-89843A • U-90042 • Zaleplon • Zolpidem • Zopiclone
Phenols: Fospropofol • Propofol
Piperidinediones: Glutethimide • Methyprylon • Pyrithyldione • Piperidione
Quinazolinones: Afloqualone • Cloroqualone • Diproqualone • Etaqualone • Mebroqualone • Mecloqualone • Methaqualone • Methylmethaqualone • Nitromethaqualone
Volatiles/gases: 2-Methyl-2-butanol • Acetophenone • Acetylglycinamide chloral hydrate • Centalun • Chloral hydrate • Ethanol (Alcohol) • Paraldehyde • Trichloroethanol
Others: Bromide (Lithium bromide, Potassium bromide, Sodium bromide) • Chloralose • Chloralodol • Clomethiazole • Dichloralphenazone • Ethchlorvynol • Etomidate • Gaboxadol • Loreclezole • Methylpentynol • Metomidate • Org 25435 • Petrichloral • Sulfonmethane • Triclofos • Valerenic acid (Valerian)
GABAB agonists
1,4-Butanediol • Aceburic acid • GABOB • GHB (Sodium oxybate) • GBL • GVL
H1 inverse agonists
α1-Adrenergic antagonists
α2-Adrenergic agonists
5-HT2A antagonists
Melatonin agonists
Agomelatine • LY-156,735 • Melatonin • Ramelteon • Tasimelteon
Orexin antagonists
Others
Drugs from TiHKAL

2-Methyl-5-HT • 4-Acetoxy-DET • 4-Acetoxy-DiPT • 4-Acetoxy-DMT • 4-Acetoxy-MiPT • 4-AcO-MET • 4-HO-αMT • 4-HO-DiPT • 4-HO-MET • 4-MeO-DMT • 4-Methyl-αET • 4-Methyl-αMT • 4,5-DHP-DMT • 4,5-MDO-DMT • 4,5-MDO-DIPT • 5-Benzyloxytryptamine • 5-Bromo-DMT • 5-Carboxamidotryptamine • 5-Ethoxy-αMT • 5-Fluoro-αMT • 5-HO-αMT • 5-HTP • 5-Ethoxy-DMT • 5-Ethyl-DMT • 5-Fluoro-DMT • 5-Methyl-DMT • 5-Methoxytryptamine • 5-MeO-7,N,N-TMT • 5-Methyl-αET • 5-MeO-αET  • 5-MeO-αMT • 5-MeO-DALT • 5-MeO-DET • 5-MeO-DiPT • 5-MeO-DMT • 5-MeO-DPT • 5-MeO-MALT • 5-MeO-MiPT • 5-MeO-NBpBrT • 5,7-Dihydroxytryptamine • 5-(Nonyloxy)tryptamine • 6-Fluoro-αMT • 7-Methyl-αET • 7-Methyl-DMT • αET • αMT • Aeruginascin • AL-37350A • BW-723C86 • Baeocystin • Bufotenidine • Bufotenin • DALT • Desformylflustrabromine • DET • DiPT • DMT • DPT • Ethocybin • EiPT • EMDT • EPT • Ethocin • FGIN-127 • FGIN-143 • Ibogaine • Indorenate • Iprocin • MET • MiPT • MPT • Miprocin • Melatonin • MS-245 • NAS • NMT • Norbaeocystin • Normelatonin • Oxypertine • PiPT • Psilocin • Psilocybin • Rizatriptan • Serotonin • Sumatriptan • Tryptamine • Tryptophan • Yohimbine • Yuremamine • Zolmitriptan
Retrieved from "http://en.wikipedia.org/w/index.php?title=Melatonin&oldid=479750798"
Personal tools
Namespaces

Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages